How we think about cardiovascular risk has changed a lot. We used to focus on total cholesterolTotal cholesterol adds together the cholesterol in all your particles, harmful and helpful alike. and later LDL cholesterolLDL cholesterol, or LDL-C, is the amount of cholesterol sitting inside your LDL particles. It is the number on almost every standard lab report. (LDL-C) as the main villains. Now, the picture is more precise: risk is driven by how many atherogenic particlesAtherogenic particles are the ApoB-containing lipoproteins—including LDL, IDL, VLDL, and lipoprotein(a)—that can enter and be retained in the artery wall to initiate and sustain plaque growth; the article uses the term to describe what must be lowered substantially and sustainably to achieve plaque regression. are circulating, which genetically “high-risk” particles are present, and how much inflammationInflammation is your immune system's response to injury or something it treats as an invader. It brings swelling, heat, and cleanup cells. is active in the vessel wall. At the heart of this newer view is a practical triad of biomarkersA biomarker is something measurable in the body that tells you about health or disease — a lab value, a scan result, a blood pressure reading.: apolipoproteinAn apolipoprotein is a protein attached to a fat-carrying particle in your blood. Fat and water don't mix, so these proteins act like a wrapper that lets fat travel safely through the bloodstream. B-100 (ApoBApoB is a protein that sits on the outside of every cholesterol particle that can get stuck in your artery wall and cause plaque. Each of those particles carries exactly one ApoB.), which counts the number of atherogenic lipoproteinA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel. particles;¹ lipoprotein(a)Lipoprotein(a), written Lp(a) and said "L-P-little-a," is an LDL-like particle with an extra sticky protein attached. [Lp(a)], a mostly inherited LDL-like particle with added thrombotic risk;² and high-sensitivity C-reactive proteinC-reactive protein, or CRP, is a substance your liver makes when there is inflammation somewhere in your body. A sensitive version of the test, hs-CRP, is used to estimate heart risk. (hsCRP), a marker that tracks systemic and vascular inflammation.³

LDL-C still matters and remains the standard therapeutic target, but clinical experience (and growing evidence) shows that LDL-C can miss important risk—especially when ApoB is high, Lp(a) is elevated, or hsCRP suggests ongoing inflammation.⁴ In many patients, these three factors stack together and create risk that feels “out of proportion” to traditional lipid panels. When you compare this biochemical and genetic risk profile with behavioral insults like cigarette smokingSmoking damages the lining of your blood vessels, raises blood pressure, makes blood clot more easily, and speeds up plaque growth., the hierarchy of risk becomes even more nuanced, reinforcing the need for personalized prevention strategies in both primary and secondary preventionSecondary prevention is treating someone who has already had a heart attack, stroke, or stent, to stop the next one..⁵

The Molecular Framework of Apolipoprotein B-100 and Particle Pathogenicity

AtherosclerosisAtherosclerosis is the disease behind most heart attacks and many strokes. Cholesterol particles get stuck in the wall of an artery, the body sends immune cells to clean up, and over years that mess hardens into plaque. doesn’t start because the blood contains “too much cholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it.” in the abstract. It starts because too many atherogenic particles are circulating, and a fraction of them get trapped in the arteryAn artery is a blood vessel that carries blood away from the heart to the rest of the body. wall.⁶ The single best way to understand this is to think in terms of particle number, not just cholesterol mass.⁶

Apolipoprotein B (ApoB) is the key structural proteinProtein is the nutrient your body uses to build and repair muscle and tissue. on all potentially atherogenic lipoproteins: very-low-density lipoproteins (VLDLVLDL, or very-low-density lipoprotein, is the particle your liver makes to ship triglycerides out to the rest of the body.), intermediate-density lipoproteins (IDLIDL, or intermediate-density lipoprotein, is a particle that forms partway through the process of a big triglyceride-carrying particle shrinking down into an LDL particle.), low-density lipoproteins (LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls.), and also lipoprotein(a).⁸ Each of these particles carries exactly one ApoB-100ApoB-100 is the full-length form of apolipoprotein B found on LDL, VLDL, IDL, and remnant lipoproteins; its positively charged amino-acid domains bind ionically to negatively charged proteoglycan side chains in the arterial wall, physically trapping the particle in the intima and initiating plaque formation. molecule, which makes ApoB a convenient biological “counter”: the ApoB concentration in plasma tells you how many atherogenic particles are present.⁷

This is why relying exclusively on LDL-C can be misleading in some common clinical settings—especially hypertriglyceridemia, metabolic syndromeMetabolic syndrome is a cluster of five problems that tend to travel together: a large waist, high triglycerides, low HDL, high blood pressure, and high blood sugar. Having three or more counts., and type 2 diabetesDiabetes is a condition where blood sugar stays too high, either because the body makes too little insulin or because it stops responding to the insulin it makes..⁶ In these states, LDL particles often carry less cholesterol per particle, shifting toward small, dense LDL (sdLDL). That means a patient can show an “acceptable” LDL-C value while still having a high number of LDL particles—a pattern often described as LDL-C/ApoB discordanceA clinical pattern in which a patient's measured LDL cholesterol mass appears acceptable while the ApoB particle count is elevated, indicating more atherogenic particles than the cholesterol number alone would suggest; common in metabolic syndrome and hypertriglyceridemia..⁹ ApoB measurement bypasses that limitation by directly reflecting particle burdenParticle burden refers to the total number of atherogenic lipoprotein particles circulating in the plasma, best measured by ApoB; it is distinguished from cholesterol mass because it is the physical count of particles — not the amount of cholesterol they carry — that determines how frequently lipoproteins infiltrate and become entrapped in the arterial wall., which better captures the likelihood of lipoprotein entry into the arterial intimaThe intima is the innermost layer of an artery wall, sitting just beneath the smooth lining..⁷

Mechanisms of Subendothelial Infiltration and Retention

Atherosclerosis begins when the endotheliumThe endothelium is the ultra-thin, slippery lining on the inside of every blood vessel. It is only one cell thick.—normally a smooth barrier—becomes more permeable or dysfunctional, often due to shear stress, oxidative injury, metabolic dysfunction, or chemical exposure (including tobacco smoke).¹¹ Once that barrier is compromised, ApoB-containing particlesLipoproteins—including LDL, IDL, VLDL, and their remnants—that each carry one molecule of apolipoprotein B on their surface; particle number (rather than cholesterol mass alone) is a key driver of atherosclerosis because each particle can be retained in the arterial wall. can move into the arterial intima.¹⁰

What matters next is not only entry, but retention. In the subendothelial spaceThe subendothelial space is the narrow gap just beneath the artery's inner lining, between that single layer of cells and the muscle beneath., ApoB particles interact with the extracellular matrixThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. rather than simply drifting by concentration gradients.¹² ApoB-100 contains positively charged regions that bind to negatively charged sulfate groups on arterial proteoglycans. This electrostatic interaction is one of the reasons particles become “stuck” in the vessel wall—an essential early step in plaquePlaque is the buildup of cholesterol, immune cells, scar tissue, and calcium inside an artery wall. formation.¹⁰ Once trapped, particles undergo oxidative and enzymatic modification, generating oxidized lipoproteins that are far more inflammatory and immunogenic than native particles.¹³

These modified particles act like danger signals. They recruit monocytes, promote macrophageA macrophage is a large immune cell that swallows debris and invaders. The name literally means "big eater." uptake through scavenger receptors, and drive the formation of lipid-laden foam cellsA foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope.—one of the earliest histologic hallmarks of atherosclerotic lesionsIn cardiology, a lesion refers to a discrete area of atherosclerotic plaque narrowing a coronary artery, typically described by the percentage of luminal obstruction it causes. The article describes four residual lesions too small in vessel diameter to accept a stent after the most critical one was treated..¹³

Stoichiometry and Diagnostic Precision of ApoB

ApoB’s clinical advantage is not only conceptual—it’s practical. Much of routine LDL-C reporting still depends on calculated methods, most commonly the Friedewald equationA widely used mathematical formula that estimates LDL cholesterol from total cholesterol, HDL cholesterol, and triglycerides rather than measuring it directly; it becomes unreliable when triglycerides are elevated or blood is drawn in a non-fasting state, which is one reason ApoB measurement is considered more accurate in certain patients.:¹⁴

This approach becomes less accurate when triglyceridesTriglycerides are the main form of fat in your blood and in your body's storage. are elevated (typically when TG exceed ~3.5–4 mmol/L) or when blood is drawn in a non-fasting state.¹⁴ ApoB, in contrast, is measured directly through immunoassays (immunoturbidimetric or immunonephelometric methods) that have been internationally standardized.¹⁵ In practice, ApoB tends to show lower analytic bias and better reproducibility than calculated lipid measures, which is why it is increasingly favored for assessing particle-driven risk.⁷

Lipoprotein(a): The Genetic Vanguard of Atherothrombosis

Lp(a) is one of the most clinically important (and frustrating) lipoproteins because it is largely genetically determined and minimally affected by lifestyle changes. Structurally, Lp(a) looks like an LDL particle with an attached additional protein—apolipoprotein(a) [apo(a)]—linked to ApoB-100 by a disulfide bond.² It’s this additional apo(a) component that makes Lp(a) biologically distinctive and often more dangerous than standard LDL. Some estimates suggest it may be several-fold more potent as a driver of cardiovascular diseaseCardiovascular disease is the umbrella term for problems with the heart and blood vessels, including heart attacks, strokes, and blocked leg arteries. than LDL alone.¹⁶

Genetic Regulation and Kringle IV Complexity

Lp(a) levels are mainly controlled by the LPA geneLPA is the gene that determines how much lipoprotein(a) you make. Your version is fixed at conception. on chromosome 6q26–q27. Lp(a) concentration is typically 70% to 90% heritable and remains relatively stable over a lifetime, unlike LDL-C which can shift substantially with diet, weight lossWeight loss means reducing body fat, whether through food changes, exercise, medication, or surgery., and medications.¹⁷ The striking variability in Lp(a) between individuals—sometimes over a 1000-fold range—comes largely from copy-number variation in the Kringle IV type 2 (KIV2) repeatsLooped protein domains within apolipoprotein(a) whose copy number varies widely between individuals; people with fewer KIV2 repeats produce smaller apo(a) isoforms and tend to have higher plasma Lp(a) concentrations, accounting for much of the inherited variability in Lp(a) levels. within apo(a).¹⁸

Kringle domains are looped structures stabilized by disulfide bonds. Apo(a) contains multiple kringle subtypes (KIV1–KIV10), but KIV2 is the one that varies widely across people. Those with fewer KIV2 repeats generally make smaller apo(a) isoforms and tend to have higher plasma Lp(a) levels. This inverse relationship between apo(a) size and Lp(a) concentration explains much of the genetic contribution to cardiovascular risk from Lp(a).¹⁹

The Dual Mechanisms of Lp(a) Pathogenicity

Lp(a) increases risk through two main pathways that overlap in real-world disease: a pro-atherogenic/pro-inflammatory pathway and a pro-thrombotic/anti-fibrinolytic pathway.²²

Atherogenic and pro-inflammatory drive: Like other ApoB particles, Lp(a) can cross the endothelium and accumulate in the intima. But Lp(a) is also a major carrier of oxidized phospholipids (OxPL) in plasma.²⁰ OxPL behave like strong inflammatory ligands, promoting endothelial activation, smooth muscle proliferation, macrophage dysfunction, and sometimes apoptosis—features that contribute to plaque growth and instability.²⁰

Thrombotic and anti-fibrinolytic interference: Apo(a) shares significant structural homology with plasminogenA blood protein that is converted to the clot-dissolving enzyme plasmin; apo(a) in Lp(a) shares strong structural homology with plasminogen, allowing Lp(a) to competitively interfere with clot breakdown..²¹ Because of this resemblance, Lp(a) can compete with plasminogen for binding sites on fibrin, interfering with plasmin generation and impairing fibrinolysisThe physiological process by which the body dissolves blood clots through the enzyme plasmin; Lp(a) impairs this process by competing with plasminogen for fibrin-binding sites, reducing clot clearance and increasing the risk of an occlusive cardiac event..²² In effect, Lp(a) encourages thrombus persistence, increasing the chance that plaque rupturePlaque rupture is when the protective cap over a plaque tears open, spilling its contents into the bloodstream. leads to a clinically significant occlusive event such as myocardial infarctionSee Heart Attack for the full entry..²²

Systemic Inflammation and the Sentinel Role of hsCRP

Atherosclerosis is now widely understood as a chronic inflammatory condition affecting the arterial wall.²³ Among the inflammatory biomarkers available clinically, hsCRP remains the most commonly used and best standardized.³ hsCRP does not tell you where inflammation is coming from, but persistent low-grade elevation strongly correlates with vascular inflammatory risk.³

The NLRP3 Inflammasome and CRP Induction

When cholesterol crystalsWhen cholesterol accumulates past what a plaque can hold in solution, it crystallizes into sharp needle-like structures. and oxidized ApoB particles build up in the intima, they activate immune pathways, including the NLRP3 inflammasomeThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability. in macrophages.²⁴ This leads to processing of pro-interleukin-1β and pro-IL-18 into active cytokines.²⁴ These cytokines stimulate downstream IL-6Interleukin-6, or IL-6, is a signaling molecule the immune system uses to spread an inflammatory message through the body. signaling, which triggers the liver to synthesize and release CRP.²⁵

CRP can spike dramatically during infection, but chronically elevated hsCRP (often defined as hsCRP ≥ 2 mg/L) behaves more like a “smoke detector” for ongoing vascular inflammation and future cardiovascular events.³

Lessons from the JUPITER Trial

The JUPITER trialThe JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial enrolled individuals with 'normal' LDL-C but elevated hs-CRP and showed that rosuvastatin significantly reduced cardiovascular events in this population, demonstrating that inflammatory risk exists and is clinically significant even when conventional cholesterol metrics appear acc… was a turning point because it showed that inflammatory risk can identify high-risk patients even when LDL-C looks fine.²⁶ The study enrolled individuals with LDL-C below usual treatment thresholds (<130 mg/dL) but with hsCRP ≥2.0 mg/L. Participants receiving rosuvastatinRosuvastatin, sold as Crestor, is the most potent statin available and stays largely in the liver rather than spreading through the body. 20 mg daily had a 44% reduction in major cardiovascular events.²⁶ Clinically, the takeaway was simple: some patients carry substantial risk through inflammation even when they do not appear “hyperlipidemic” by LDL-C alone.

Mapping the Interplay: Synergistic Risk and Pathogenic Cross-talk

ApoB, Lp(a), and hsCRP do not operate in isolation. Their relationship is better described as interactive, with overlapping mechanisms that can amplify each other’s harm.⁴

High ApoB means more particles enter the vessel wall and more substrate becomes available for oxidative modification. Those modified particles intensify inflammation, raising hsCRP. Inflammation then further disrupts endothelial functionThe ability of the inner lining of blood vessels to regulate vascular tone, inflammation, and clotting; healthy endothelial cells release nitric oxide to keep arteries relaxed and resistant to plaque formation., making it easier for additional ApoB particles to enter—creating a self-reinforcing loop.²³

This synergy shows up clearly in large population studies. In a study of over 320,000 UK BiobankUK Biobank holds detailed genetic, lifestyle, and health data on half a million British volunteers, linked to their medical records. participants, LDL-C, Lp(a), and hsCRP were each independently associated with major adverse cardiovascular eventsA major adverse cardiovascular event, or MACE, is a bundle of bad outcomes counted together in a study — typically cardiovascular death, heart attack, and stroke. (MACE), but the combined effect was far greater than any single marker alone.⁴

Comparison of Biomarker Risks to the Pathogenic Impact of Smoking

Smoking remains one of the most aggressive cardiovascular toxins because it generates oxidative stressOxidative stress is an imbalance between damaging reactive molecules and the body's ability to neutralize them., drives chronic inflammation, and directly injures the endothelium.²⁷ The question clinicians often ask is: how does smoking compare to lipid and biomarker risk?

INTERHEARTINTERHEART was a large international case-control study that compared risk factors in people who had had a first heart attack against matched controls across 52 countries. The article cites its finding that permanent general stress carried an odds ratio of 2.17 for myocardial infarction, with psychosocial factors together accounting for a population-attributable risk of roughly 32.5%. provides one of the most useful comparisons because it included diverse populations across 52 countries.⁵ It showed that current smoking had one of the highest individual odds ratios for MI, but dyslipidemiaDyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination. (measured by ApoB/ApoA1 ratioA lipid risk metric comparing the concentration of ApoB (reflecting all atherogenic particles) to ApoA1 (reflecting HDL, the primary reverse-cholesterol-transport particle); used in INTERHEART as a proxy for dyslipidemia, it had an odds ratio of 3.43 for myocardial infarction and the highest population attributable risk of any single risk factor studied.) carried an even larger population attributable risk, because dyslipidemia is so common globally.²⁸

The Female Paradox: Sex-Specific Risk Sensitivities

Large cohorts show that women may experience a greater relative increase in MI risk from certain exposures, especially smoking and metabolic dysfunction.²⁹ In UK Biobank, current smoking was linked to a hazard ratioA hazard ratio compares how quickly events happen in two groups. A ratio of 0.75 means events occurred at three-quarters the rate in the treated group. for MI of 3.46 in women compared with 2.23 in men, producing a ratio of hazard ratios (RHR)A comparison of the hazard ratio for a given exposure (such as smoking) in one group (women) versus another (men), used to quantify sex-specific differences in risk; an RHR greater than 1.0 indicates the exposure is relatively more harmful in the first group. of 1.55.²⁹

Clinical Implications: Managing the Residual Risk Triad

Even with excellent statin therapy and strong LDL-C lowering, cardiovascular events still occur. This is often referred to as residual riskResidual risk is the risk that remains after you have done the obvious things — cholesterol treated, blood pressure controlled, not smoking., and it commonly reflects a combination of residual particle risk (ApoB), genetic risk (Lp(a)), and residual inflammatory riskResidual inflammatory risk refers to the persistent elevation of cardiovascular event rates in patients who have already achieved guideline-recommended LDL-C targets but continue to have elevated inflammatory markers such as hsCRP; it represents a second, parallel pathway of atherogenesis that lipid-lowering alone does not address. (hsCRP).³⁰

Statins lower LDL-C and reduce events, but they have little effect on Lp(a), and multiple studies suggest statins may increase Lp(a) modestly (often ~10–20%).³¹ PCSK9 inhibitorsA PCSK9 inhibitor is a medicine that blocks that cholesterol-destroying protein, leaving more docking ports available to clear particles from the blood. reduce LDL-C substantially and also lower Lp(a) by about ~27%.³²

The most promising future approach is direct Lp(a) lowering using antisense oligonucleotides (ASOs) or siRNA platforms, which have shown 80–90% reductions in early studies.³³ Finally, inflammation-focused trials such as CANTOSCANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) was a large randomized trial that tested canakinumab, a drug blocking the inflammatory signal IL-1β, against placebo; at its prespecified 150 mg dose it reduced major cardiovascular events by roughly 15% without lowering LDL cholesterol, providing direct human evidence that inflammation drives heart attacks through a pathway indepen… demonstrated that reducing inflammatory signaling (independent of lipids) can reduce MACE, reinforcing the clinical reality that inflammation is not just a bystander.³⁴

Conclusion: The Integrated Risk Map

Preventive cardiology is increasingly moving from a single-marker “cholesterol hypothesis” toward a more integrated approach. In practical terms, ApoB tells you particle burden, Lp(a) tells you inherited atherothrombotic risk, and hsCRP tells you about inflammatory activation. When these risks cluster, events can occur despite “good” LDL-C numbers.

Used together, these markers support more individualized decisions about therapy intensity and emerging targeted treatments—aimed at achieving the deepest possible reduction in cardiovascular risk.

References

1. Nicholls SJ, Nelson AJ. Current perspectives on Lp(a)-lowering therapies: Who may benefit?. Kardiol Pol. 2025;83(6):688-694. doi:10.33963/v.phj.106327
2. Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
3. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813-1818. doi:10.1161/01.cir.103.13.1813
4. Markus MRP, Ittermann T, Mariño Coronado J, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J. 2025;46(39):3863-3874. doi:10.1093/eurheartj/ehaf281
5. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. doi:10.1016/S0140-6736(04)17018-9
6. Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk: The Debate Is Over. JAMA Cardiol. 2022;7(3):257-258. doi:10.1001/jamacardio.2021.5080
7. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
8. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016
9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-113. doi:10.1016/j.jacl.2011.02.001
10. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832-1844. doi:10.1161/CIRCULATIONAHA.106.676890
11. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509-515. doi:10.1161/ATVBAHA.113.300156
12. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016;27(5):473-483. doi:10.1097/MOL.0000000000000330
13. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108(2):235-248. doi:10.1161/CIRCRESAHA.110.223875
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
15. Albers JJ, Marcovina SM. Standardization of apolipoprotein B and A-I measurements. Clin Chem. 1989;35(7):1357-1361.
16. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176-184. doi:10.1161/CIRCULATIONAHA.107.715698
17. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52-60. doi:10.1172/JCI115855
18. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607-614. doi:10.1007/BF00201550
19. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15(2):167-174. doi:10.1097/00041433-200404000-00009
20. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230-2239. doi:10.1194/jlr.M800174-JLR200
21. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132-137. doi:10.1038/330132a0
22. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37(5):333-343. doi:10.1016/j.clinbiochem.2003.12.007
23. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874. doi:10.1038/nature01323
24. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357-1361. doi:10.1038/nature08938
25. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145-156. doi:10.1161/CIRCRESAHA.115.306656
26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646
27. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-1737. doi:10.1016/j.jacc.2003.12.047
28. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224-233. doi:10.1016/S0140-6736(08)61076-4
29. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247. Published 2018 Nov 7. doi:10.1136/bmj.k4247
30. Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016;37(22):1720-1722. doi:10.1093/eurheartj/ehw024
31. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-2284. doi:10.1093/eurheartj/ehz310
32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
33. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020;382(3):244-255. doi:10.1056/NEJMoa1905239
34. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914